Ramucirumab monotherapy showed survival benefits in patients.577 Apatinib is a selective VEGFR2 small molecule tyrosine kinase inhibitor approved in China.594 Phase III clinical trial showed that apatinib monotherapy can increase the OS of repeatedly treated GC patients.595 Lenvatinib and regorafenib are multikinase inhibitors with anti-VEGFR activity. This evidence concerns the gene KDR and gastric cancer.